Clinical studies
These results encourage the idea that surfactant treatment might reduce the severity and incidence of RDS. Several different techniques have been investigated and tried. They vary from using almost whole natural animal surfactant to completely synthetic protein-free mixtures of phospholipids. Nevertheless, it cannot be emphasized too strongly that however impressive some of the results may appear, most of the clinical data are either on very small numbers or are not satisfactorily controlled so that any proper interpretation of the results is virtually impossible. Natural surfactants Smyth and colleagues (1983) in Toronto have been using the surfactant nearest to natural surfactant, which is centrifuged, Folch extracted, calf lung wash. They reported treating 6 babies, ventilated for RDS during the first day with 200 mg of surfactant in 8 ml saline. There was an improvement in oxygenation in 5 of the babies. The initial improvement deteriorated by 24 hours. The need for considerable respiratory support was not eliminated. Two babies developed considerable long-term respiratory problems. There were no controls. The use of this surfactant is now the subject of a controlled randomized trial in Toronto. Hallman and colleagues (1983) have ingeniously extracted natural human surfactant by density gradient centrifugation from mature amniotic fluid obtained from term caesarian sections, and shown that it improves pressure/volume curves in premature rabbits. This has been the subject of a small published trial (Schneider et al. 1982) , used as 60 mg/kg of surfactant in 3.5 ml saline given intratracheally to 5 babies with severe RDS within the first ten hours of life. There was considerable improvement in oxygenation in the first hour. In 4 cases the respiratory distress stabilized for 8-15 hours after surfactant treatment, during which time mean airway pressure and especially oxygen requirements were considerably lower than before treatment. Thereafter, respiratory distress recurred. The fifth patient only experienced transient improvement. There were no controls. Berggren and colleagues (1983) have extracted natural surfactants from pig lung wash. This apparently has very satisfactory surface tension properties. In preliminary use in ventilated babies with RDS it is reported as improving the oxygenation. The results of a properly randomized trial are eagerly awaited. Fujiwara et al. (1979) extracted surfactant from minced cow lungs and then improved its properties with extra DPPC and PG so that they closely resembled those of natural surfactant. It also has good effects on the pressure/volume curves of premature rabbit lungs.
Semi-synthetic surfactant
It has been used in a clinical trial of 105 mg/kg in 10 ml saline delivered into the endotracheal tube of babies with established RDS (Fujiwara et al. 1980 ). The 10 babies treated had dramatic improvements in their oxygenation and could be ventilated with slightly lower peak pressures. However they remained intubated, receiving respiratory support for an average of 13 more days. This appeared to be due to several of the babies developing severe complications from patent ductus arteriosus. One of the difficulties with this study is the lack of controls. More babies have been treated since this trial was published, with apparently satisfactory outcome.
Artificial surfactants
The early trials of nebulized surfactant mixtures by Robillard et al. (1964) , Chu et al. (1967) , Ivey et al. (1976) and Shannon et al. (1969) are rather difficult to interpret because the techniques of managing RDS have changed, the dose delivered is unknown (if any) and there were no controls. However, there did seem to be a slight improvement in the babies which may have been due to the treatment.
In 1981 Morley and colleagues published the results of the preliminary non-randomized trial of dry powdered artificial surfactant (DPPC: PG, 7: 3) blown down the endotracheal tube of resuscitated premature babies of less than 34 weeks gestation at birth. This artificial surfactant has physical properties, when used in a dry crystalline state, which are comparable to the properties of natural surfactant (Robertson 1981 , Bangham et al. 1979 . In this clinical trial the surfactant only seemed to be effective in the premature babies of 27-29 weeks gestation. It reduced the mortality and amount of treatment required. This trial has differed from the others in that the surfactant was given at birth, as a powder in a relatively small dose. Although control babies were included, they were not strictly randomized. This preliminary trial has now been extended to a full controlled randomized trial which will include 360 babies. Halliday and colleagues (1984) have recently published the results of a randomized trial. They studied the effects of an artificial surfactant made from a mixture of 30 mg DPPC and 3 mg human plasma high-density lipoprotein sonicated in 5 ml saline. In this study 100 babies of less than 34 weeks gestation were randomized to surfactant treatment or nothing. They were all electively intubated at birth and the surfactant delivered down the endotracheal tube. There were no significant differences between the groups although there was a trend towards improved survival in the treated babies of 27-29 weeks gestation.
Experimental studies During the last few years, a great deal of background work on surfactant treatment has been undertaken, so that we now have a better knowledge of what to use, how it works and what to expect. Jobe and colleagues (1981) have shown that although natural surfactant treatment of premature lambs improves lung function, it has its limitations. It only seemed to be effective in the most premature lambs with the poorest lung function. Those lambs which were physiopathologically similar to premature babies with RDS were not affected. They also showed that if the surfactant was given to very premature lambs at birth, there was improvement but this lasted only 8 hours and at the the end of that time the lambs were in severe respiratory failure. If the lambs were treated when respiratory failure was established, the benefit lasted only 3 hours. A second treatment was often ineffective. When the airway surfactant was examined from similar lambs after the animals had deteriorated, it was found that the surface tension properties of the surfactant had been lost (Jacobs et al. 1982) . This was shown to be, at least partially, due to exuded proteins interfering with the surface properties of the phospholipids.
When radioactively-labelled natural surfactant was instilled into the trachea of full-term lambs, it was incorporated into the lamellar bodies and had a half-life of about 6 days ). This, with other studies, suggests that exogenous surfactant may not only have immediate physical effects but also act as substrate for further surfactant synthesis.
In some of the studies there have been problems with the babies or animals developing patent ductus arteriosus causing pulmonary oedema. This has been investigated. It appears that the increased shunt was not due to increased prostaglandin E2 or alterations in the ductal resistance, but that the surfactant caused a significant drop in pulmonary vascular resistance (Clyman et al. 1982 , Bayten et al. 1983 ). Hurt and colleagues (1983) have delivered a cautionary tale about the effect on premature lambs of different techniques of delivering different types of surfactant. Lambs subjected to the same procedures used to deliver some of the surfactants, but without the benefit of surfactant, developed improvements in lung function that were nearly equal to the surfactant-treated lambs. This stresses the need for proper controls for all the studies.
A number of groups have been actively trying to produce better semisynthetic or artificial surfactants. One of the problems is that there is as yet no 'gold standard' of properties against which these surfactants can be tested. In consequence, claims are made for the effectiveness of surfactants which other workers find difficult to substantiate. Recently a Japanese team have meticulously defined many of the important biochemical and physical properties of lung surfactant (Tanaka et al. 1983a , b, Tanaka & Takei 1983 ). It appears from their work and others that the following in vitro criteria are essential for the lung surfactant to give normal pressure/volume characteristics to mammalian lung in situ and in vivo.
(I) Surfactant spreads spontaneously on an aqueous surface and within seconds produces an equilibrium surface tension below 35 mN/m.
(2) The surface tension falls to 10 mN/m or less when the surface area is compressed by up to 50% of the starting area.
(3) These characteristics are quickly reproducible on compression and expansion of the surface film.
One of the major areas of disagreement among workers in this field is whether there is a surfactant-specific protein which is vital for the correct physical function. Some workers claim that only surfactant with this protein is effective. Others state that all the necessary properties can be produced without any protein, and that it is often deleterious to surfactant function and may sensitize the infants and cause later allergic reactions.
Conclusion
This is an exciting and rapidly advancing field. These preliminary trials and their tantalizing results have encouraged a flurry of activity in the area of surfactant treatment so that around the world 13 different trials are in operation or plan to start soon, all using different surfactants, different delivery techniques and doses. All the evidence suggests that within the next few years there will be artificial surfactants for use in the treatment of hyaline membrane disease. However, a final cautionary note is required. The data on the clinical trials so far, although apparently impressive, are actually very anecdotal. The best surfactant to use in babies, its dosage and technique of delivery are still far from established. It also seems that there is now enough evidence to show that surfactant treatment is unlikely to be the magic cure for RDS that perhaps it was expected to be. Premature babies who develop RDS have many different problems, i.e. immature lung structure, difficulty clearing their lung fluid, proteinaceous exudation onto the alveolar surface, poor muscle tone, erratic respiratory drive and patent ductus arteriosus. These will not be solved by surfactant treatment, although the severity of such children's respiratory problems will probably be improved to an extent where the severest complications of RDS are no longer being seen.
